Ozempic Just Lost Its Monopoly in a G7 Country

And Canada is just one front in a global campaign. Here's what's happening elsewhere:

Brazil approved its first semaglutide alternative (called Ozivy, made by EMS) in May 2026, though Brazil's regulator Anvisa classified it as a non-generic product under Brazilian regulation. India has multiple approvals already, including from Sun Pharma, Zydus Lifesciences, and Alkem Laboratories. China has about 17 generic semaglutide candidates in late-stage development, with several expecting approval before the end of the year.

The pattern is clear: in every country where semaglutide patents have expired (or lapsed), competitors are arriving fast.

What This Means for Novo Nordisk's $25 Billion Franchise

Ozempic and Wegovy together generated roughly $26 billion in sales in 2024. In Q1 of 2025, the two drugs accounted for about 64% of Novo Nordisk's total revenue. This isn't a side business; it's the whole business.

Novo's own 2026 guidance acknowledges the pressure. The company explicitly warned of "negative impacts from the compound patent expiry of the semaglutide molecule in certain markets" and "intensifying competition." Some analysts expect Novo to report flat or declining sales and operating profit in 2026, a stark contrast to years of explosive growth.

But perspective matters. The really big shoe hasn't dropped yet. U.S. patents on semaglutide don't expire until 2032, and European protection runs until roughly 2031. The American market, where Novo generates the lion's share of revenue, remains a walled garden for another six years. BMO Capital Markets analyst Evan Seigerman has said companies like Novo can "absorb the impact of generic competition on pricing," at least for now.

Think of it like a castle losing its outer walls while the inner keep stays fortified. The perimeter is breached, but the core holds.

Aspen's Unusual Playbook

Aspen Pharmacare isn't your typical generic drug company. The South African firm built its reputation manufacturing low-cost HIV drugs for Africa, becoming the first generic company globally accredited to PEPFAR (the U.S. government's massive HIV treatment program). It later pivoted to branded generics, specialty products, and partnerships with companies like Amgen and Eli Lilly for biosimilars.

Canada is a strategic beachhead for Aspen, not a final destination. The company plans to use its Canadian approval as a reference market for expanding generic semaglutide into emerging economies across Latin America, Africa, and beyond.

There's one catch, though: Aspen depends on Dr. Reddy's Laboratories in India for the active pharmaceutical ingredient (the actual semaglutide compound). Regulatory approval is one thing; having enough drug to sell is another. Aspen has said its commercial launch timing hinges entirely on API supply. Getting the recipe approved doesn't help if you can't source the ingredients.

The Affordability Question

For Canadian patients, generic semaglutide could mean real savings. Brand-name Ozempic runs roughly CAD $200 to $500 per month out of pocket. Analysts expect generics to bring that down to the CAD $80 to $120 range as competition intensifies.

But lower prices won't automatically translate to broader coverage. Most Canadian provincial health plans already cover semaglutide for type 2 diabetes, so generic entry mainly reduces costs for those patients and their insurers. For people who want semaglutide for weight loss, the picture is murkier. Provincial formularies generally don't cover it for obesity alone, and a cheaper generic doesn't change that policy overnight.

The dynamic is: affordability improves first, coverage second. Cash-paying patients benefit immediately. Those relying on public insurance may wait longer, especially for obesity indications.

The Bigger Picture

This approval matters less for what it is (one more generic in one market) and more for what it signals. The semaglutide monopoly era is ending, country by country. By late 2026, generic versions will be available in nations representing over 40% of the world's population, including India, China, Brazil, and Canada.

Novo Nordisk still holds a dominant position in the GLP-1 market. Those numbers will come under pressure, but they won't collapse tomorrow. The real test arrives in 2032, when U.S. patents expire and generic makers can finally compete in the market that matters most.

Until then, Canada offers a preview of what that future looks like: more options, lower prices, and a lot more competition for a drug that changed modern medicine.

Two Minutes to Decide If You Need Wegovy

Former LifeMD employees allege clinicians had just two minutes per patient to prescribe powerful GLP-1 weight-loss drugs. The STAT News investigation puts Novo Nordisk's entire telehealth strategy under a harsh spotlight.